Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has reported a loss for its fourth fiscal quarter (ending September 30) of $-1.33 versus a loss $-1.27 for the same period a year ago. This result exceeded the consensus estimate of $-2.21 by $0.88. E.P.S. were $-6.38 for the latest four quarters through September 30 versus $-5.91 for the same period a year ago.
Recent Price Action
On 11/20/23, Enanta Pharmaceuticals Inc (NASDAQ: ENTA) stock suffered a large decline of -2.1%, closing at $8.94. Relative to the market the stock has been extremely weak over the last nine months but has risen 8.2% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be in line with the cost of capital, ENTA is expected to continue to be Value Creation neutral.
Enanta Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Enanta Pharmaceuticals has a neutral Appreciation Score of 45 but a very low Power Rating of 3, leading to the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment